Sunshine Biopharmas Wholly Owned Canadian Subsidiary Engages Health Canada Specialized Consultants to Secure Pharmaceutical Establishment License - KPLC 7 News, Lake Charles, Louisiana

Sunshine Biopharmas Wholly Owned Canadian Subsidiary Engages Health Canada Specialized Consultants to Secure Pharmaceutical Establishment License

Posted: Updated:

Montreal, Quebec, Canada / ACCESSWIRE / August 21, 2014 / Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has engaged consultants specialized in Health Canada procedures and requirements to prepare the necessary documentations and applications for the procurement of a Pharmaceutical Establishment License.  Such licensing must be in place before the Company is able to sign manufacturing and distribution contracts and accept purchase orders for the sale of pharmaceutical products.

“We are anxious to have our Pharmaceutical Establishment License in place in order to be able to capitalize on attendant opportunities with a potential to generate revenues in the near term,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma.  “Profits from such operations will be used to fund our proprietary drug development program including Adva-27a, our flagship oncology drug candidate currently being developed for the treatment of Pancreatic Cancer and Multidrug Resistant Breast Cancer.  This will make us less dependent on capital markets for financing of our drug development operations.”

About Adva-27a

Adva-27a is Sunshine Biopharma’s lead anticancer compound, a small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).  Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.  The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University’s Jewish General Hospital in Montreal (Canada).

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.

ReleaseID: 419414

Powered by WorldNow